Akorn Inc. has announced approval of an FDA new drug application (NDA) for ophthalmic gel 3.5% (Akten), a topical, ocular anesthetic formulation.
Modern Medicine Now
Adjuvant use of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) with ranibizumab (Lucentis, Genentech) reduced the reduced the number of ranibizumab injections needed to control choroidal neovascularization secondary to age-related macular degeneration. Use of the two drugs together resulted in better visual acuity outcomes than those achieved with ranibizumab alone.
Prevent Blindness America (PBA) announced it has been awarded a 3-year cooperative agreement from the Centers for Disease Control and Prevention (CDC), with a first-year grant of $1 million.
Advanced Medical Optics (AMO) announced that the FDA has granted premarket approval of a clear dispersive ophthalmic viscosurgical device (OVD) (Healon D) for use as a surgical aid in cataract extraction, IOL implantation, corneal transplant, and glaucoma filtration surgery.
A novel gene therapy approach for the treatment of a type of inherited retinal disease appears to be safe and effective in initial trials. Results offer hope for the treatment of a gamut of eye diseases that once were thought to be untreatable, according to one researcher.
Once you get employees to realize that their success or failure ultimately is up to them, the pressure is off you as a manager. The pressure is squarely in the place it needs to be: on the employees. Your only job then becomes augmenting their growth with the tools they need to be the hardest-working technicians you ever will have.
A 19-year-old Latin female presented to the Bascom Palmer emergency room complaining of transient black spots in the right eye.
Children who have convergence insufficiency (CI) will respond better to weekly treatment sessions with a trained vision therapist than to a strictly home-based eye exercise program, according to a study released by the National Institutes of Health (NIH).